Healthcare apparel company Figs (NYSE:FIGS) announced better-than-expected revenue in Q3 CY2025, with sales up 8.2% year on year to $151.7 million. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates. Is now the time to buy FIGS? Find out in our full research report (it’s free for active Edge members). Figs (FIGS) Q3 CY2025 Highlights: Revenue: $151.7 million vs analyst estimates of $142.5 million (8.2% year-on-year growth, 6.4% beat) Adjusted EPS: $0.05 vs ana ...